Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SCANLUX-370 vs OMNIPAQUE 350
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
Intravascular administration for computed tomography (CT) and angiography,Opacification of body cavities such as arthrography and hysterosalpingography
Intravascular procedures: angiography, urography, venography, CT enhancement,Intrathecal administration: myelography (lumbar, thoracic, cervical),Oral/rectal administration: GI tract opacification
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
1-2 m L/kg IV up to 150 m L for CT; 30-50 m L IV for DSA; max 350 m L per procedure.
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Not metabolized; excreted unchanged via glomerular filtration.
For patients with GFR 30-60 m L/min: reduce dose by 50%. For GFR <30 m L/min: use is contraindicated.
GFR 30-59 m L/min: reduce dose by 50% or use alternative; GFR <30 m L/min: contraindicated.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 25%. Class C: use with caution, maximum dose 0.05 mg/kg.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes mellitus, or dehydration.
Iodinated contrast media, including ioxaglate (SCANLUX-370), cross the placenta. First trimester exposure: Theoretical risk of fetal thyroid dysfunction from excess iodine; no documented teratogenicity in human studies. Second and third trimester: Can cause transient neonatal hypothyroidism if administered near term; avoid unless essential. Use only when diagnostic benefit outweighs potential risk.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Iodinated contrast crosses the placenta. Potential fetal hypothyroidism if high doses administered near term, particularly in premature infants. First trimester: theoretical risk from free iodide; second trimester: no known teratogenicity; third trimester: risk of neonatal hypothyroidism if maternal thyroid function compromised. Use only if clearly needed.
SCANLUX-370 is a contrast agent for CT imaging. Administer via IV bolus at 1-2 m L/s. Monitor for hypersensitivity reactions especially in patients with asthma or allergies. Pre-warming to body temperature reduces viscosity and injection-related discomfort. Ensure adequate hydration pre- and post-procedure to minimize renal injury risk. Do not mix with other drugs in the same syringe.
Pre-warm OMNIPAQUE 350 to body temperature to reduce viscosity and improve patient comfort during injection. Monitor renal function before administration; use lowest dose necessary in patients with CKD or diabetes. Have emergency equipment available for anaphylactoid reactions. For CT angiography, time bolus with test injection or bolus tracking.
No interactions on record
No interactions on record
SCANLUX-370 and OMNIPAQUE 350 are distinct pharmacological agents. SCANLUX-370 belongs to the Radiographic Contrast Agent class and is primarily used for Intravascular administration for computed tomography (CT) and angiographyOpacification of body cavities such as arthrography and hysterosalpingography. OMNIPAQUE 350 belongs to the Radiographic Contrast Agent class and is primarily used for Intravascular procedures: angiography, urography, venography, CT enhancementIntrathecal administration: myelography (lumbar, thoracic, cervical)Oral/rectal administration: GI tract opacification. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SCANLUX-370 carries a safety status of Category C, whereas OMNIPAQUE 350 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Not metabolized; excreted unchanged by glomerular filtration with renal clearance; negligible hepatic metabolism.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
SCANLUX-370 exhibits negligible protein binding, with less than 5% bound to plasma proteins, primarily albumin. The low binding ensures rapid distribution and clearance.
Negligible (<5%). Iohexol does not bind significantly to plasma proteins.
The volume of distribution (Vd) is approximately 0.25-0.3 L/kg, indicating distribution primarily within the extracellular fluid space. This low Vd reflects limited tissue penetration, consistent with its use as an extracellular contrast agent.
Approximately 0.26 L/kg, indicating distribution primarily within extracellular fluid.
SCANLUX-370 is administered intravenously and has 100% bioavailability via this route. Oral bioavailability is negligible (less than 1%) due to poor gastrointestinal absorption and extensive first-pass metabolism.
Not applicable for intravenous administration; bioavailability is 100% intravenously.
Child-Pugh A: no adjustment; Child-Pugh B/C: consider risk/benefit; no formal dose guidelines.
For children aged 2-12 years: 0.05 mg/kg intravenously, max 3 mg. For infants 6-24 months: 0.03 mg/kg, max 1.5 mg.
0.5-2 m L/kg IV (max 3 m L/kg) based on age and indication.
No specific dose adjustment required, but monitor renal function; consider starting at the lower end of the dosing range due to age-related decline in renal function.
Use lowest effective dose; monitor renal function; dose adjustment based on GFR as for adults.
Risk of fatal anaphylactoid reactions, especially in patients with history of allergic reaction, asthma, or sensitivity to iodine. Emergency resuscitation equipment and trained personnel must be immediately available.
No known food interactions. However, patients are typically advised to avoid solid food for 4 hours prior to contrast-enhanced imaging to reduce risk of aspiration if vomiting occurs.
No specific food interactions. However, patients should avoid food 2-4 hours prior to procedures requiring sedation or anesthesia. Maintain adequate hydration before and after contrast administration.
Ioxaglate is excreted into breast milk in minimal amounts; M/P ratio not established. Theoretical risk of direct iodine exposure to infant; consider interrupting breastfeeding for 12-24 hours post-dose with pumping and discarding milk. Infant monitoring for thyroid function not routinely required but caution advised.
Iohexol is excreted into breast milk in minimal amounts (less than 0.1% of maternal dose). M/P ratio not established. Estimated infant dose less than 1% of maternal weight-adjusted dose. American College of Radiology states breastfeeding can continue without interruption, but some experts suggest discarding milk for 12-24 hours post-administration. No adverse effects reported in nursing infants.
Pregnancy induces increased plasma volume and renal blood flow, potentially increasing clearance of ioxaglate. However, standard weight-based dosing may be insufficient; consider dose adjustment based on estimated glomerular filtration rate (e GFR) to maintain diagnostic image quality while minimizing fetal exposure. No established pregnancy-specific dosing guidelines; clinical judgment required.
No specific dose adjustment is required for pregnancy. However, due to increased plasma volume and glomerular filtration rate in pregnancy, standard weight-based dosing provides adequate opacification. Use lowest dose necessary to obtain diagnostic information. Consider iodinated contrast as risk-benefit decision, especially in cases of known or suspected fetal hypothyroidism or maternal thyroid disorder.
Inform your doctor if you have allergies, asthma, kidney problems, or are taking metformin.,Drink plenty of water before and after the procedure to help protect your kidneys.,You may experience a warm sensation or metallic taste during injection; this is temporary.,Report any difficulty breathing, hives, itching, or swelling immediately after contrast administration.,Breastfeeding should be avoided for 24 hours after receiving this contrast agent.
Inform your doctor if you have any allergies, especially to iodine or contrast media.,Drink plenty of fluids before and after the procedure to help flush the contrast from your kidneys.,You may experience a warm sensation, metal taste, or nausea during injection; these are temporary.,Tell your doctor if you are pregnant, breastfeeding, or have kidney problems, diabetes, or take metformin.,After the procedure, monitor for signs of delayed allergic reaction such as rash, itching, or difficulty breathing.